Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Immune modulation: IL-1, master mediator or initiator of inflammation

There are many ways to modulate the immune response in a therapeutic setting. Drugs that target the proinflammatory mediator IL-1, for instance, can counteract disease in certain types of inflammatory conditions. But such drugs do not work well for other conditions, such as rheumatoid arthritis and other autoimmune diseases. New clinical studies, examined by Kingston Mills and Aisling Dunne, provide insight into this discrepancy. Another approach that has worked well in mice harnesses the ability of regulatory T cells to dampen the immune response. But one barrier in the way of successful application to people is the ability of such cells to change their character for the worse. Massimo Gadina and John O'Shea take a look at a basic research study that highlights this dilemma and examine what it means for the future of human trials.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: IL-1 in autoinflammatory and autoimmune diseases.


  1. Dinarello, C.A. Annu. Rev. Immunol. 27, 519–550 (2009).

    CAS  Article  Google Scholar 

  2. Masters, S.L., Simon, A., Aksentijevich, I. & Kastner, D.L. Annu. Rev. Immunol. 27, 621–668 (2009).

    CAS  Article  Google Scholar 

  3. Aksentijevich, I. et al. N. Engl. J. Med. 360, 2426–2437 (2009).

    CAS  Article  Google Scholar 

  4. Reddy, S. et al. N. Engl. J. Med. 360, 2438–2444 (2009).

    CAS  Article  Google Scholar 

  5. Geddes, K., Magalhaes, J.G. & Girardin, S.E. Nat. Rev. Drug Discov. 8, 465–479 (2009).

    CAS  Article  Google Scholar 

  6. Martinon, F., Burns, K. & Tschopp, J. Mol. Cell 10, 417–426 (2002).

    CAS  Article  Google Scholar 

  7. Sutton, C., Brereton, C., Keogh, B., Mills, K.H. & Lavelle, E.C. J. Exp. Med. 203, 1685–1691 (2006).

    CAS  Article  Google Scholar 

  8. Mills, K.H. Eur. J. Immunol. 38, 2636–2649 (2008).

    CAS  Article  Google Scholar 

  9. Sutton, C.E. et al. Immunity 31, 331–341 (2009).

    CAS  Article  Google Scholar 

  10. Brydges, S.D. et al. Immunity 30, 875–887 (2009).

    CAS  Article  Google Scholar 

  11. Meng, G., Zhang, F., Fuss, I., Kitani, A. & Strober, W. Immunity 30, 860–874 (2009).

    CAS  Article  Google Scholar 

  12. Bianchi, M.E. J. Leukoc. Biol. 81, 1–5 (2007).

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Kingston H G Mills.

Ethics declarations

Competing interests

K.H.G.M. is a cofounder, minority shareholder, consultant, and scientific advisory board member of Opsona Therapeutics, Ltd.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Mills, K., Dunne, A. Immune modulation: IL-1, master mediator or initiator of inflammation. Nat Med 15, 1363–1364 (2009).

Download citation

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing